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DOI 10.1016/j.ccr.2011.10.030SUMMARYMalignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this
process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregu-
lated in melanoma, the functional implications of this observation are unclear. By modulating b-catenin
levels in a mousemodel of melanoma that is based onmelanocyte-specific Pten loss and BrafV600E mutation,
we demonstrate that b-catenin is a central mediator of melanoma metastasis to the lymph nodes and lungs.
In addition to altering metastasis, b-catenin levels control tumor differentiation and regulate both MAPK/Erk
and PI3K/Akt signaling. Highly metastatic tumors with b-catenin stabilization are very similar to a subset of
human melanomas. Together these findings establish Wnt signaling as a metastasis regulator in melanoma.INTRODUCTION
Malignant melanoma is the most deadly form of skin cancer, and
its incidence is increasing both in the United States and world-
wide (Purdue et al., 2008). Nearly all melanoma deaths are a
result of metastasis, which can occur early in disease progres-
sion, even from thin primary tumors (Bedrosian et al., 2000).
Recent advances in melanoma therapeutics have led to
improved survival in patients with metastatic melanoma,
however, prognosis is still poor for most patients (Hodi et al.,
2010; Chapman et al., 2011). Despite an improving under-
standing of the genetic alterations present in humanmelanomas,
how these changes relate to the metastatic process is not wellSignificance
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Canunderstood. Metastasis is difficult to study in vitro, making
the use of mouse models central to the functional evaluation of
the roles of genetic changes observed in human melanomas
in the metastatic process.
b-catenin associates with E-cadherin as part of the adherens
junction and can also interact with the T cell factor/lymphoid
enhancer factor (TCF/LEF) to activate the transcription of target
genes as part of the canonical Wnt signaling pathway. b-catenin
mutations were originally found to be present in 23% of mel-
anoma cell lines (Rubinfeld et al., 1997) and have since been
consistently described in about 5% of primary, uncultured mel-
anomas (Omholt et al., 2001; Demunter et al., 2002; Reifenberger
et al., 2002; Forbes et al., 2010). Nuclear b-catenin, which isis. Despite an improved understanding of genetic changes
e metastatic process is unclear. Here, using an inducible
n by some of the most common alterations found in human
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b-Catenin Controls Melanoma Metastasisthought to reflect canonical Wnt pathway activation, is present in
approximately one-third of human melanoma specimens (Rimm
et al., 1999). The mechanisms of b-catenin dysregulation are
likely diverse but are at least in part due to mutations both in
b-catenin as well as other Wnt pathway components (reviewed
by Larue and Delmas, 2006). Subsequent analyses have also re-
ported abnormal cellular localization of b-catenin in the cyto-
plasm and nucleus of melanomas (Silye et al., 1998; Sanders
et al., 1999; Omholt et al., 2001; Kageshita et al., 2001; Demunter
et al., 2002; Kielhorn et al., 2003; Tucci et al., 2007; Chien et al.,
2009). The consequences of this dysregulation, as well as the
functional implications of b-catenin activating mutations in vivo,
remain somewhat unclear. For example, whereas Wnt signaling
activation has been shown to contribute to melanoma formation
in mice (Delmas et al., 2007), other studies have reported that
increased b-catenin staining is associated with improved sur-
vival in melanoma patients (Chien et al., 2009). These findings
suggest that the results of Wnt/b-catenin signaling activation
are complex and likely context-dependent.
b-catenin is important for normal melanocyte biology and is
required for survival of melanocytes from neural crest precursors
(Hari et al., 2002). Part of this requirement relates to the direct
transcriptional activation of MITF by b-catenin when Wnt sig-
naling is activated. MITF is a transcription factor that regulates
melanocyte function and survival. Similarly to b-catenin, MITF
is dysregulated in melanoma, where it is has been shown to be
amplified in 10% of primary and 21% of metastatic melanomas
(Garraway et al., 2005). The functional impact of MITF amplifica-
tion and overexpression in humanmelanoma are also somewhat
unclear (Garraway et al., 2005; Ugurel et al., 2007; Nazarian et al.,
2010). The implications of the activation of both Wnt signaling
and melanocytic differentiation in human melanomas remain
unresolved and highlight the need for systematic in vivo evalua-
tion of the relation between Wnt/MITF alterations and disease
progression in the context of the genetic alterations that are
commonly observed in human melanomas.
In this study, we utilized a conditional mouse model of mela-
noma that is based on melanocyte-specific Pten loss and the
BrafV600E activating mutation in order to help clarify the role of
Wnt/b-catenin signaling and downstream factors, such as
MITF in melanoma formation and progression. By either inacti-
vating or stabilizing b-catenin in thesemelanomas, the functional
role of b-catenin was specifically evaluated. The mouse models
of melanoma generated in this study were closely characterized
and compared to human melanomas with analogous genetic
changes.
RESULTS
b-Catenin Loss Inhibits Melanoma Formation
in Pten/Braf-Driven Melanomas
In order to evaluate the role of canonicalWnt signaling and b-cat-
enin in melanoma formation and progression, we used a previ-
ously characterized conditional mouse model of melanoma
that is based on melanocyte-specific Pten-inactivation and the
BrafV600E activating mutation (Dankort et al., 2009). In this model
(henceforth referred to as the ‘‘Pten/Braf’’ model), genetic
recombination of floxed alleles and melanoma formation occurs
after topical application of 4-hydroxtamoxifen (4-HT). Further-742 Cancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Incmore, mice develop melanoma from endogenous melanocytes,
closely recapitulating the complex nature of tumor initiation
and formation in a physiologically accurate microenvironment.
In the Pten/Braf model, just these two genetic changes are
sufficient to cause melanoma in 100% of mice within one month
of generalized tumor induction by topical application of 4-HT
(Figure 1A; Dankort et al., 2009).
To study the role of endogenous b-catenin inmelanoma forma-
tion and progression, b-catenin was inactivated in the Pten/Braf
model by using a previously characterized conditional knockout
Ctnnb1 allele (Brault et al., 2001; referred to asBcat-KO). In these
mice, wild-type b-catenin is expressed in melanocytes until Cre-
mediated recombination results in b-catenin inactivation at the
time of tumor induction. Pten/Braf/Bcat+/ or Pten/Braf/Bcat/
(KO) mice were perinatally treated with topical 4-HT in order to
induce generalized recombination in melanocytes. In mice in
which both copies of b-catenin were inactivated, a significant
increase in median survival was observed relative to the Pten/
Brafmice (Figure 1A). Although pigmented lesions did eventually
develop in Pten/Braf/Bcat-KO mice, melanoma formation was
significantly delayed, especially on footpads and peri-oral skin
andmucosa (Figure 1B). Histologically,Pten/Braf/Bcat-KOmela-
nomas invade deep into the dermis and subcutis. In contrast with
Pten/Brafmelanomas, which are pigmented, these tumors show
only rare pigmented tumor cells and exhibit focal nerve sheath-
like histopathological features (Figure 1C).
Pten/Braf melanomas metastasize to draining lymph nodes in
100% of mice that were perinatally treated with 4-HT (Dankort
et al., 2009). However, when b-catenin is inactivated, metastatic
tumor cells in draining lymph nodes become undetectable, even
at up to 80 days of age (Figures 1B and 1D). These findings
suggest that endogenous b-catenin is important both in mela-
noma formation, as well as in the subsequent spread of tumor
cells to draining lymph nodes. Melanomas did not form when
b-catenin was inactivated in the context of either BrafV600E muta-
tion or Pten loss alone, demonstrating that b-catenin inactivation
does not promote tumorigenesis in the context of these indi-
vidual oncogenic changes (Figure S1A available online).
b-Catenin Stabilization Accelerates Pten/Braf-Driven
Melanomagenesis
Activation of the canonical Wnt signaling pathway results in
stabilization, accumulation, and nuclear translocation of b-cate-
nin. In the nucleus, b-catenin interacts with the TCF/LEF family of
transcription factors and leads to transcriptional activation of
target genes, such as MYC, CCND1 (Cyclin D1), and AXIN2, as
well as melanocyte-specific transcripts, such as MITF (Larue
and Delmas, 2006; MacDonald et al., 2009). Mutations to exon
3 phosphorylation sites, which regulate b-catenin stability,
provide an alternate means for increasing b-catenin activity,
even in the absence of Wnt ligands (Omholt et al., 2001; De-
munter et al., 2002; Reifenberger et al., 2002). In light of the inhib-
itory effect of b-catenin loss in Pten/Braf melanomas and the
prevalence of b-catenin stabilizing mutations in human mela-
nomas, we tested the effects of b-catenin stabilization in the
Pten/Braf tumor model. In order to do this, Pten/Braf mice
were crossed with mice bearing the previously characterized
Ctnnb1loxex3 allele (Harada et al., 1999). Prior to recombination,
wild-type b-catenin is expressed in melanocytes, but after.
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Figure 1. b-Catenin Loss Inhibits Melanoma Formation in Pten/Braf-driven Melanomas
(A) Survival analysis of Pten/Braf cohorts after perinatal/generalized tumor induction.
(B) Comparison of Pten/Braf/Bcat+/ (top) and Pten/Braf/Bcat-KO (bottom) tumor burden at 28 days of age. Metastasis to inguinal lymph node is also shown
(right panels).
(C) H&E stained Pten/Braf/Bcat-KO flank tumor, scale 300 mM (top) and 10 mM (bottom).
(D) Quantification of metastasis to the inguinal lymph nodes in Pten/Braf/Bcat-KO mice (n = 13) compared to Pten/Braf mice (n = 8). Error bars represent SEM.
See also Figure S1.
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b-Catenin Controls Melanoma MetastasisCre-mediated excision of exon 3, a stabilized (degradation-
resistant) version of b-catenin is expressed (Bcat-STA allele).
Mutations in human melanomas almost always affect exon 3
phosphorylation sites (Forbes et al., 2010) and result in analo-
gous stabilization of b-catenin.
After generalized induction of recombination, Pten/Braf/Bcat-
STA mice exhibit reduced survival relative to Pten/Braf mice
(Figures 2A and 2B). By the time of weaning, Pten/Braf/Bcat-
STA mice are moribund with heavily pigmented tumors (Figures
2C and 2D). Necropsy revealed enlarged, pigmented lymph
nodes in all mice, which were confirmed to contain metastatic
melanoma (Figures 2C and 2E). Upon histological examination,
tumors were markedly pigmented throughout their entire thick-
ness and tumor cells could be found surrounding and directly
abutting the microvasculature.
Melanomas also formed in mice with Braf activation and
b-catenin stabilization in the presence of wild-type Pten after
generalized induction of recombination. These tumors, in
contrast with the Pten/Braf/Bcat-STA tumors, had a very long
latency, with a median survival of 250 days (Figure 2A). Braf/
Bcat-STA tumors generally grew very slowly and were heavily
pigmented (Figure 2F). Approximately 10% of tumors exhibited
more rapid growth, which was always accompanied by relative
loss of melanocytic differentiation antigen expression (TableCanS1). In contrast with the Pten/Braf/Bcat-STA model, neither
manifestation of the Braf/Bcat-STA model exhibited distant
metastasis.
b-Catenin Signaling Controls the Ability of Melanomas
to Metastasize to Lung, Bowel, and Spleen
As most melanoma deaths are due to metastasis to distant
organs, we characterized the pattern of visceral metastasis in
Pten/Braf melanomas with altered b-catenin status. In Pten/
Braf/Bcat-STA mice, lung metastases were present at nearly
a 100-fold greater frequency than in Pten/Braf/Bcat-KO mice
(Figures 3A and 3B and S2A–C). The metastases were irregular
in shape and ranged in size from <0.1mm to >0.5 mm (Figure 3C
and S2A–C). These pigmented metastases stained strongly for
the melanocytic marker Tyrp1 (Figure S2D–E). b-catenin stabili-
zation in Pten/Braf melanomas also resulted in metastasis to
other visceral sites, such as bowel and spleen (Figure 3D–3G).
Locally Induced Melanomas are Highly Metastatic
and Can Form Lethal Metastases
The conditional and inducible nature of thismousemodel system
allows for the generation of small, anatomically restricted mela-
nomas by focal application of a small volume of 4-HT to adult
mice (Dankort et al., 2009). Using this approach, rather thancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Inc. 743
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Figure 2. b-Catenin Stabilization Accelerates Pten/Braf-Driven Melanomagenesis
(A) Survival analysis of cohorts with b-catenin stabilization after perinatal tumor induction.
(B) Survival analysis of Pten/Braf littermates, either with or without b-catenin stabilization, after perinatal tumor induction.
(C) Tumor phenotype in Pten/Braf/Bcat-STA mice (top panels) compared to non-tumor prone mice (bottom panels) at 21 days of age.
(D) H&E stained Pten/Braf/Bcat-STA flank tumor, scale 500 mM. Right panel: high power of outlined field, scale 20 mM.
(E) H&E stained tumor-draining lymph node from a Pten/Braf/Bcat-STA mouse, scale 400 mM. High power of outlined field, scale 20 mM, right panel.
(F) H&E stained nevi (left panel) and tumor (right panel, arrow) from a Braf/Bcat-STA mouse, scale 500 mM (left) and 500 mM (right).
See also Table S1.
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b-Catenin Controls Melanoma Metastasisthe generalized, perinatal inductions used until this point, mela-
nomas were induced on the flank skin of Pten/Braf mice with
wild-type, inactivated, or stabilized b-catenin. Melanocytic
proliferations generally became grossly apparent approximately
two weeks after induction of recombination, growing to 1 cm
tumors by four to eight weeks, at which point mice were eutha-
nized for analysis (Figure 4A). When b-catenin was stabilized,
tumors grew more rapidly to 1 cm (Figure S3A). Melanomas still
formed in mice with inactivation of both copies of b-catenin (Fig-
ure 4A). PCR combined with western blotting and immunohisto-
chemistry confirmed recombination of floxed Ctnnb1 alleles as
well as the predicted changes to b-catenin at the protein level
(Figure S3B–D). When b-catenin was stabilized, it was frequently
found in the nucleus of tumor cells, and the stabilized protein
(lacking exon 3) could be visualized by western blot. In Pten/
Brafmelanomas, wild-type b-catenin was generally found within
the cytoplasm but could also be visualized in the nucleus. b-cat-
enin staining was absent in tumor cells from Pten/Braf/Bcat-KO
mice.
In addition to changes in b-catenin, these tumors displayed
vastly different histology (Figure 4B).Pten/Braf/Bcat-STA tumors
were characterized by large pigmented cells that were present
throughout the thickness of the tumor. Pten/Braf tumors were
characterized by increased edema in deeper parts of the tumor,744 Cancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Incin which tumor cells were often relatively smaller in size. Similarly
to the generalized tumor inductions, Pten/Braf/Bcat-KO mela-
nomas had relatively little pigmentation, bland spindled cytology,
and often exhibited areas of nerve sheath-like differentiation.
Metastases were infrequent in mice with locally induced Pten/
Braf melanomas with either wild-type or inactivated b-catenin.
However, when b-catenin was stabilized, lung metastases and
expansile lymph node metastases were prevalent (Figure 4C).
In the various iterations of the Pten/Braf model, flank mela-
nomas grow rapidly, leaving little time for metastasis to occur.
To circumvent this issue and develop models in which morbidity
andmortality were directly related to metastases, rather than the
primary tumor, two approaches were taken. First, tumors were
induced on the distal tail of Pten/Braf/Bcat-STA mice (Fig-
ure S3F). Second, localized tumors were induced on the flank
in Braf/Bcat-STA mice that had only one copy of Pten inacti-
vated (Figures 4A and 4B). Both approaches resulted in slower
primary tumor growth, allowing mice to be followed for metas-
tasis for up to one year. Clinically symptomatic metastases
developed in two-ninths of tail melanoma-bearing mice and in
one-fifth of flank melanoma-bearing mice (Figures S3E and
S3G; Table S2). Similar approaches in Pten/Braf mice, without
b-catenin stabilization, resulted in primary tumor formation, but
not distant metastasis (Table S2)..
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Figure 3. b-Catenin Signaling Controls the Ability of Melanomas to Metastasize to Lung, Bowel, and Spleen
(A) Lungs from a perinatally treated Pten/Braf/Bcat-STAmouse at 27 days of age (left panel) and a perinatally treated Pten/Braf/Bcat-KOmouse at 56 days of age
(right panel).
(B) Comparison of number of lung metastases visible on the surface of the lung in perinatally treated litters. Error bars represent SEM.
(C) Lung metastasis from a perinatally treated Pten/Braf/Bcat-STA mouse, scale 100 mM.
(D) Bowel metastasis from a perinatally treated Pten/Braf/Bcat-STA mouse.
(E) Comparison of number of bowel metastases in perinatally treated litters.
(F) H&E stained spleen metastasis from a perinatally treated Pten/Braf/Bcat-STA mouse, scale 200 mM.
(G) Comparison of number of spleen metastases in perinatally treated litters.
See also Figure S2.
Cancer Cell
b-Catenin Controls Melanoma MetastasisEnhanced Metastasis in Pten/Braf/Bcat-STA
Melanomas Is Accompanied by an Increase in
Melanocytic Differentiation Markers
Pten/Braf/Bcat-STA tumors were much more pigmented than
were Pten/Braf tumors (Figure 5A–5B). Pten/Braf tumors
showed pigmented melanoma cells at the superficial aspect of
the tumor, whereas deeper parts of the tumor were edematous
and amelanotic. In contrast, Pten/Braf/Bcat-STA melanomas
were heavily pigmented and remained so, even in deeper
portions of the tumor. As the expression of many melanocytic
pigmentation genes is controlled by MITF-M, a melanocyte-
specific isoform of MITF that is a transcriptional target of
b-catenin/LEF1 (Widlund et al., 2002; Cheli et al., 2010), we
investigated alterations to both Wnt and Mitf target genes in
these tumors. qRT-PCR using RNA prepared directly from
uncultured tumors showed transcriptional upregulation of both
canonical Wnt and Mitf target genes in Pten/Braf/Bcat-STACantumors (Table S3). Conversely, many of these transcripts were
downregulated in Pten/Braf/Bcat-KO tumors. Increased or
decreased Mitf-M levels were confirmed by qRT-PCR and
western blot analysis (Figure 5C and 5D). Global expression
profiling was also performed on a subset of uncultured mela-
nomas, which more broadly supported these trends in both
Wnt and Mitf target gene expression. Together, these models
encompass a continuum of b-catenin/Mitf transcriptional
activity in the context of Pten loss and Braf activation.
Pten/Braf/Bcat-STA melanomas show the highest, Pten/Braf/
Bcat-KO, the lowest, and Pten/Braf an intermediate level of
b-catenin/Mitf transcriptional activity (Table S3). Activated tran-
scriptional activity of endogenous b-catenin in Pten/Brafmodels
is also supported by the presence of S552 phosphorylation of
b-catenin in this model (Figure S3D), a posttranslational modifi-
cation associated with nuclear translocation and transcriptional
activation (Zhang et al., 2010).cer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Inc. 745
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Figure 4. Locally Induced Melanomas are Highly Metastatic and Can Form Lethal Metastases
(A) Survival analysis of cohorts after localized tumor induction. Mice were euthanized when tumors reached 1 cm.
(B) H&E stained sections of locally induced tumors from a Pten/Braf/Bcat-STAmouse (top panels, scale 20 mM left, 20 mM right), a Pten/Brafmouse (upper middle
panels, scale 100 mM left, 50 mM right), a Pten/Braf/Bcat-KOmouse (lower middle panels, scale 400 mM left, 50 mM right), and a Braf/Bcat-STA/Pten+/mouse
(bottom panels, scale 400 mM left, 50 mM right).
(C) Quantification of lung (left panel) and lymph node (right panel) metastasis in mice with focally induced melanomas. Error bars represent SEM.
See also Figure S3 and Table S2.
Cancer Cell
b-Catenin Controls Melanoma MetastasisIncreased levels of melanocyte differentiation markers in
Pten/Braf/Bcat-STA tumors are also present at the protein level.
Pten/Braf/Bcat-STA tumors have elevated Tyrp1 staining rela-
tive to Pten/Braf tumors (Figure 5E), and they also stain strongly
for S100 (Figure 5F). Other melanocytic differentiation markers,
such as Kit, Mitf, Met, and E-cadherin, are also increased at
the protein level (Figure 5D and S4A–C). N-cadherin levels
were also highest inPten/Braf/Bcat-STAmelanomas (Figure 5D).
Initially, the finding of increased melanocytic differentiation
seemed somewhat counterintuitive as tumor metastasis is often
thought to be associated with relative loss of differentiation
markers. Along these lines, we decided to determine the effects
of conditional inactivation of E-cadherin in the Pten/Braf/Bcat-
STA model. E-cadherin loss is thought to result in increased
metastasis in some cancers (Kalluri and Weinberg, 2009). Along
these lines, E-cadherin loss in Pten/Braf/Bcat-STA melanomas
might be predicted to further facilitate metastasis if differentia-
tion in these tumors was functionally restricting metastasis.
However, when E-cadherin was inactivated in these tumor
cells, neither primary tumor growth nor metastasis was altered
(Figure 5G–5H). These data support the notion that enhanced
differentiation in melanocytic tumors does not functionally
restrict metastasis and can even be associated with increased
metastasis.
b-Catenin Stabilization Is Associated with
Hyperactivation of PI3K/Akt and MAPK/Erk Signaling
As reduced levels of differentiation did not seem to promote or
even correlate with enhanced metastasis, we next compared
activation of core pathways mediating growth and proliferation:746 Cancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier IncMAPK/Erk and PI3K/Akt. Protein lysates were prepared from
uncultured melanomas with either wild-type, stabilized, or inac-
tivated b-catenin. Pten/Braf/Bcat-STA tumors tended to exhibit
a relative decrease in phosphorylated Erk and p90Rsk compared
with Pten/Braf and Pten/Braf/Bcat-KO tumors (Figure 6A). Previ-
ously, it has been proposed that very high levels of Erk phos-
phorylation may actually impede proliferation (Cheung et al.,
2008). Furthermore, it has been recently suggested that an
18-gene transcriptional signature may be the best indicator of
MAPK pathway activity in tumor cells (Packer et al., 2009; Dry
et al., 2010). In order to complement the phospho-protein anal-
ysis and gain a more comprehensive understanding of MAPK
pathway activation in these tumors, we also investigated the
expression of this gene set. In fact, most of these 18 genes
were upregulated in Pten/Braf/Bcat-STA tumors relative to
Pten/Braf tumors, which suggests that the transcriptional output
of the MAPK pathway may actually be elevated, despite slightly
attenuated phosphorylated Erk levels (Figure S5A). Increased
MAPK/Erk signaling in Pten/Braf/Bcat-STA melanomas was
accompanied by an increased Ki67 index and mitotic figure
count relative to Pten/Braf tumors (Figure S5B). As MITF has
been shown to be required for proliferation induced by BrafV600E
(Wellbrock et al., 2008), it could be reasonably hypothesized that
increased Mitf in Pten/Braf/Bcat-STA tumors may be related to
MAPK pathway hyperactivation.
Next, we checked the phosphorylation status of Akt at S473 and
T308, two phosphorylation events required for full activation of Akt
(Guertin and Sabatini, 2007). Pten/Braf/Bcat-STA tumors showed
an increase in both phosphorylation events, in addition to in-
creases in total Akt protein levels (Figure 6B). Pten/Braf/Bcat-KO.
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Figure 5. Enhanced Metastasis in Pten/Braf/Bcat-STA Melanomas Is Accompanied by an Increase In Melanocytic Differentiation Markers
(A) Locally induced flankmelanoma (upper left panel) with H&E (upper right panel, scale 400 mM) and draining lymph node (lower left panel, scale 500 mM)with H&E
(lower right panel, scale 500 mM) in a Pten/Braf/Bcat-STA mouse.
(B) Locally induced flank melanoma (upper left panel) with H&E (upper right panel, scale 400 mM) and draining lymph node (lower left panel, scale 500 mM) with
H&E (lower right panel, scale 500 mM) in a Pten/Braf mouse.
(C) Mean expression of Mitf-M determined by qRT-PCR from Pten/Braf/Bcat-STA, Pten/Braf, and Pten/Braf/Bcat-KO melanomas (n = 4 per genotype).
Expression levels normalized to GAPDH control. Error bars represent SEM.
(D) Western blots using protein lysates prepared directly from uncultured flank melanomas. M, normal cultured melanocytes.
(E) Tyrp1 immunofluorescence of locally induced Pten/Braf/Bcat-STA (left panel) and Pten/Braf (right panel) flank melanomas, scale 200 mM.
(F) S100 immunohistochemistry of a locally induced Pten/Braf/Bcat-STA melanoma from an albino mouse, scale 100 mM.
(G) Survival analysis of Pten/Braf/Bcat-STAmice with or without E-cadherin inactivation after perinatal tumor induction. NS, not statistically significantly different.
(H) Quantification of lung metastases in perinatally induced Pten/Braf/Bcat-STA mice with or without E-cadherin inactivation. Error bars represent SEM.
See also Figure S4 and Table S3.
Cancer Cell
b-Catenin Controls Melanoma Metastasistumors showed decreased Akt activation and protein levels. The
phosphorylation status of Akt substrates (Pras40 and Gsk3b)
also supported this trend (Figure 6B). The activation status ofCanmTORC1, which lies downstream of Akt, also seemed highest in
Pten/Braf/Bcat-STA melanomas, which had relatively elevated
phosphorylationofS6,an indicator ofmTORC1activity (Figure6B).cer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Inc. 747
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Figure 6. b-Catenin Stabilization Is Associated with Hyperactivation
of PI3K/Akt and MAPK/Erk Signaling
(A–C) Western blots using protein lysates prepared from uncultured flank
melanomas. M, Normal cultured melanocytes.
See also Figure S5.
Cancer Cell
b-Catenin Controls Melanoma MetastasisAt the transcriptional level, Akt gene expression was similar
among the models, suggesting that differences in posttranscrip-
tional regulation of Akt might underlie differences in Akt protein
levels (Table S3). Pin1, a protein isomerase known to regulate
Akt stability and phosphorylation (Liao et al., 2009; Nakatsu748 Cancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Incet al., 2011), was increased in Pten/Braf/Bcat-STA tumors and
decreased in Pten/Braf/Bcat-KO tumors (Figure 6B). Pin1 is tran-
scriptionally upregulated in Pten/Braf/Bcat-STA melanomas
(Table S3), and by increasing Akt stability, Pin1 may enable
increased levels of activated Akt protein. Furthermore, T450
turn motif phosphorylation of Akt by mTORC2 also promotes
Akt stability (Oh et al., 2010) and was highest (independent of
increases in total protein level) in Pten/Braf/Bcat-STA tumors
(Figures 6B and S5C). Taken together, these observations
suggest that Wnt signaling, by promoting Akt stability through
Pin1, can enhance PI3K/Akt pathway activty.
Increases in Akt levels and phosphorylation status in the
context of Braf activation and b-catenin stabilization seemed
to correlate most closely with a metastatic phenotype. To
address this further, we reconsidered the Braf/Bcat-STA cohort,
which has wild-type Pten and thus reduced Akt activation. These
mice form heavily differentiated melanomas that grow slowly
and do not metastasize. When Akt is activated via Pten deletion,
as in the Pten/Braf/Bcat-STAmodel, enhancedmetastasis is ob-
served in the context of increased melanocytic differentiation,
providing strong evidence that activation of Akt through loss of
Pten drives metastasis of pigmented melanomas. Interestingly,
full Akt activation in Braf/Bcat-STA melanomas was only ob-
served in a small subset of tumors and always in the context of
relative decreases in melanocyte differentiation antigen expres-
sion (Figure 6C). As neither manifestation of the Braf/Bcat-STA
melanomas (low Akt activation with high differentiation or high
Akt activation with low differentiation) metastasize, a complex
relation is implied in which both melanocytic differentiation and
Akt activation are required for metastasis in the context of
Braf/Bcat-STA melanomas.
An alternative explanation to increases in Akt activation
status and metastasis in the Pten/Braf/Bcat-STA melanomas
could involve increased receptor tyrosine kinase (RTK) expres-
sion and/or activation, which are known to signal through this
pathway. As the RTKs Kit and Met are both upregulated in
Pten/Braf/Bcat-STA melanomas, these receptors emerged as
possible mediators of this effect. In vivo functional evaluation
of the potential role of each of these receptors in mediating
the metastatic phenotype of b-catenin stabilization was evalu-
ated. Overexpression of Met in Pten/Braf melanomas by using
a doxycycline-inducible mouse strain did not recapitulate the
metastatic phenotype induced by b-catenin stabilization (Fig-
ure S5D, data not shown). This was not entirely unexpected;
although Met was overexpressed in Pten/Braf/Bcat-STA mela-
nomas, it did not appear to be activated (Figure S5E). Similarly,
inhibition of Kit receptor signaling by treating with imatinib
in Pten/Braf/Bcat-STA melanomas significantly slowed growth
of the primary tumor but did not alter the frequency of metas-
tasis (Figure S5F and 5G). These data suggest that increased
expression of Met and Kit observed in Pten/Braf/Bcat-STA
melanomas is not sufficient to explain the metastatic
phenotype.
Pten/Braf/Bcat-STA Murine Melanomas Faithfully
Recapitulate Human Melanomas
In order to understand the relevance of this model to human
melanomas, several approaches were taken. First, human mela-
noma cell lines with Braf activating mutation and Pten loss/Akt.
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Figure 7. Pten/Braf/Bcat-STA Murine Melanomas Faithfully Recapitulate Human Melanomas
(A) Fold-change in expression of individual transcripts relative to mean for each transcript compared between human and murine melanomas. PBB,
Pten/Braf/Bcat-STA; PB, Pten/Braf.
(B) GSEA was performed on human melanomas with b-catenin stabilizing mutation using a subset of differentially regulated transcripts identified using murine
melanomas, p < 0.001.
(C) Western blot analysis using protein lysates prepared from human melanoma cell lines. b-catenin status indicated for each sample.
(D) Regression analysis comparing MITF, TYRP1, and PIN1 expression in a large human melanoma expression data set.
(E) Contingency table of pigmentation status in human melanomas based on cadherin clusters (Kreizenbeck et al., 2008). O, observed; E, expected. Green, less
than expected by chance; red, greater than expected by chance.
See also Figure S6 and Table S4.
Cancer Cell
b-Catenin Controls Melanoma Metastasisactivation were identified. Within this group, we characterized
two tumors with b-catenin stabilizing mutations, one with wild-
type b-catenin and one without detectable b-catenin protein
levels. These cell lines were characterized at both the mRNA
and protein levels. The most differentially expressed transcripts
between Pten/Braf/Bcat-STA and Pten/Braf murine melanomas
were identified (Figure 7A; Table S4) and used to perform geneCanset enrichment analysis (GSEA) on the human melanoma ex-
pression data (Subramanian et al., 2005). These analyses
showed a strong concordance in the expression of this gene
subset in human melanomas with b-catenin stabilization (Fig-
ure 7B; p < 0.001). A similar methodology was also used to iden-
tify differentially expressed genes in the human melanoma cell
lines with and without b-catenin stabilization and used forcer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Inc. 749
Cancer Cell
b-Catenin Controls Melanoma MetastasisGSEAwithmousemelanoma expression data (Figure S6A; Table
S4). Melanomas with analogous changes showed significant
enrichment of these transcripts, whereas those without the
same changes exhibited an inverse relation for this gene subset
(Figure S6B, p < 0.001). Together, these analyses suggest that
the mouse and human melanomas with the same genetic
changes were more similar to each other than were melanomas
with different genetic changes but from the same species.
Western blotting, using protein lysates from these human
melanoma cell lines, showed similar changes to mouse mel-
anomas with analogous genetic changes. Melanomas with
b-catenin stabilization showed much higher expression of mel-
anocytic differentiation markers relative to tumors with wild-
type or no b-catenin (Figure 7C). Also, human melanomas with
wild-type b-catenin compared with those without b-catenin
staining, mirrored changes to MAPK and PI3K/Akt signaling
identified by comparing Pten/Braf and Pten/Braf/Bcat-KO
mouse melanomas (Figures 7C and S6C). Lastly, analysis of a
large expression dataset from a genetically diverse collection
of cultured human melanomas supported the finding that
increased b-catenin expression is associated with increased
MITF, which was, in turn, associated with increased TYRP1
and PIN1 expression (Figure 7D). Analysis of the human PIN1
promoter revealed a CATNNG motif E box (457CACATG-
452), a promoter element to which MITF is specifically known
to bind (Khaled et al., 2010). Together, these data support the
hypothesis that alterations in b-catenin levels in human mel-
anomas result in similar phenotypic changes to those observed
in the murine melanoma models.
In order to assess how frequently human melanomas exhibit
characteristics as seen in mouse models with Braf, Akt, and
Wnt signaling activation, we employed a previously published
data set (Kreizenbeck et al., 2008). Here, primary and metastatic
melanoma biopsies were stained in order to assess cadherin and
catenin expression patterns, which formed the basis for clus-
tering into four groups. One of these four clusters (cluster 4)
was characterized by relatively high levels of N-cadherin, E-cad-
herin, with several cases also showing relatively elevated b-cat-
enin. This phenotype is very similar to the Pten/Braf/Bcat-STA
mouse melanomas, which exhibit increased E-cadherin, b-cate-
nin, and high N-cadherin levels, in addition to being heavily
pigmented. To follow up on these observations, we conducted
additional analyses of this human melanoma data set, which
revealed that melanomas in cluster 4 were significantly more
pigmented than would be expected by chance, with the largest
proportion of heavily pigmented melanomas compared to other
clusters (p < 0.0001; Figure 7E). Other clinical features of these
melanomas are described in Table S4. These data support the
notion that the Pten/Braf/Bcat-STA murine melanomas closely
recapitulate an entire class of human melanomas, not just those
with Braf activation, Pten loss, and b-catenin stabilization.
DISCUSSION
The MAPK and Akt pathways are nearly universally dysregulated
in human melanomas, with specific occurrence of Pten loss
together with Braf activation in at least 20% of tumors (Tsao
et al., 2004; Curtin et al., 2005). The precise role ofWnt/b-catenin
signaling in human melanoma has remained elusive, despite750 Cancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier Incextensive in vitro study, mouse modeling efforts, and immuno-
histochemical analyses of human melanoma specimens. Here,
by characterizing mouse models that are based on genetic alter-
ations commonly observed in human melanoma, a definitive role
for b-catenin as a mediator of tumor progression and metastasis
in Pten inactivated, Braf activated melanomas has been estab-
lished. In the Pten/Brafmouse models, metastasis can be either
enhanced or repressed by either increasing or decreasing
b-catenin levels, respectively.
In recent analytical studies of human melanoma specimens, it
has been proposed that reduced b-catenin levels are associated
with a relatively worse prognosis (Chien et al., 2009). However,
when b-catenin is inactivated in Pten/Braf melanomas, tumor
formation is delayed, survival is extended, and metastasis is
nearly eliminated. These data demonstrate the requirement for
endogenous b-catenin in melanoma formation and progression.
The phenotypic alterations inPten/Braf/Bcat-KO tumors seem to
be related to decreased Wnt transcriptional output, as well as
decreasedMitf levels andMitf target gene expression. In a similar
vein, when b-catenin is stabilized in the Pten/Braf melanomas,
survival is reduced and metastasis to lymph node, lung, bowel,
and spleen is enhanced, some of the most common sites of
metastasis in human melanoma patients. In addition to being
more metastatic, Pten/Braf/Bcat-STAmelanomas are also char-
acterized by increased Wnt-related transcription, primarily as an
increase in Mitf and Mitf target gene expression. Thus, in the
Pten/Braf model, more metastatic tumors are characterized by
enhanced melanocyte differentiation, whereas less metastatic
tumors exhibit reduced melanocytic differentiation.
The relation between melanoma differentiation/pigmentation
and metastasis has long been of research interest. Twenty-five
years ago it was observed that more pigmented mouse mela-
noma cell lines had an enhanced ability to metastasize (Bennett
et al., 1986). Since this time, other work has suggested that the
melanocytic differentiation programmay intrinsically predispose
melanomas tometastasis after oncogenic transformation (Gupta
et al., 2005). The finding of Mitf amplification in >20% of meta-
static melanomas, also suggests a powerful oncogenic potential
for melanocyte differentiation programs (Garraway et al., 2005).
These observations are also supported clinically, as melanomas
are known to frequentlymetastasize early in disease progression,
even from relatively thin primary tumors (Bedrosian et al., 2000).
These observations are contrastedwith observations suggesting
that in general melanomas with increased MITF staining (and
b-catenin staining) are associated with relatively improved
survival in melanoma (Chien et al., 2009; Nazarian et al., 2010).
An improved understanding of humanmelanoma genetics has
begun to allow for classification of melanomas based on funda-
mental driving mutations, such as mutant NRAS or BRAF. Here,
specific evaluation of the consequences of b-catenin stabiliza-
tion or inactivation in the context of precisely defined genetic
changes was possible. When b-catenin is stabilized in the con-
text of Pten loss and Braf activation, melanomas are very meta-
static, grow rapidly, and are highly differentiated. However, in the
presence of wild-type Pten, Braf activation and b-catenin stabi-
lization have very different effects. Although highly differentiated
tumors form, they do not metastasize. Further, Braf/Bcat-STA
melanomas grow very slowly and it is only in association with
relative loss of melanocytic differentiation, that tumors exhibit.
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Figure 8. Signaling and Phenotypic Overview of
Murine Melanoma Models
(A) Pten/Braf/Bcat-STA melanomas are characterized by
rapid growth, high degree of melanocytic differentiation,
and extensive metastasis. These phenotypes are associ-
ated with increased MAPK/Erk and PI3K/Akt signaling, as
well as elevated Mitf and Pin1 levels. Bold text, relatively
increased levels and/or activity compared to othermodels;
blue shading, relatively decreased compared to other
models; red shading, genetically inactivated; *, stabilized.
(B) Pten/Braf melanomas exhibit rapid tumor growth but
only intermediate melanocytic differentiation and metas-
tasis. Signaling pathway activation, Mitf, and Pin1 are
intermediate in this model.
(C) Pten/Braf/Bcat-KO melanomas exhibit tumor growth
but significantly reduced melanocytic differentiation and
almost no metastasis. Inactivation of b-catenin in this
model is associated with reduced PI3K/Akt signaling and
Mitf levels.
(D) Braf/Bcat-STA melanomas are characterized by long
latency and slow tumor growth, as well as lack of metas-
tases. These tumors are differentiated and heavily pig-
mented because of high Mitf levels but show reduced
PI3K/Akt pathway activation.
(E) A three-pathway synergy is observed when MAPK/Erk,
PI3K/Akt, and b-catenin/Mitf signaling pathways are
simultaneously activated in melanoma. If any of these
three changes are not present, the metastatic melanoma
phenotype is abrogated.
Cancer Cell
b-Catenin Controls Melanoma Metastasismore rapid growth. Comparison of Pten/Braf/Bcat-STA mela-
nomas to Braf/Bcat-STA melanomas revealed that activation
of Akt in the context of Braf activation and b-catenin stabilization
is strongly associated with metastasis in the highly differentiated
melanomas. Furthermore, when one considers the amelanotic
Braf/Bcat-STA melanoma variant, in which accelerated tumor
growth occurred only in the context of relative loss of differenti-
ation markers, it becomes clear that in some contexts melano-
cytic differentiation may actually restrict exuberant melanoma
growth. It is notable that in this model loss of Pten has the poten-
tial to switch themelanocyte differentiation program froma trans-
forming, but relatively growth restrictive pathway to a pathway
that promotes growth and metastasis. It is also notable that in-
creased differentiation, which includes increased E-cadherin
expression, rather than preventing metastasis, is associated
with an increase in this process.
These findings raise the possibility that factors promoting
metastasis in one melanoma may not promote metastasis inCancer Cell 20, 741–other genetically distinct melanomas. These
considerations suggest that broadly defining
the biological effects of pathways, such as
Wnt signaling and MITF, in melanoma may not
be possible out of context of other mutational
changes and help to explain the relative incon-
sistency of previous studies in this regard.
Such context-specific roles of mutated proteins
in cancer are likely to emerge as a paradigm as
we learn better ways to classify melanomas into
biologically meaningful groups.
In the Pten/Braf melanomas, simultaneous
activation of core signaling pathways mediatinggrowth and survival correlate very closely with the ability to
metastasize. Concurrent activation of MAPK, PI3K/Akt, and
Wnt/Mitf pathways are all required for the full metastatic mela-
noma phenotype, as loss of any component abrogates the effect
(summarized in Figure 8). Furthermore, changes toWnt signaling
not only alter Wnt output and the melanoma phenotype but also
impact signaling through other core pathways regulating cellular
growth and survival. Pten/Braf/Bcat-STA melanomas show
enhanced MAPK and PI3K/Akt activation, whereas Pten/Braf/
Bcat-KO melanomas show decreased PI3K/Akt signaling. It is
likely that MAPK pathway activation in Pten/Braf/Bcat-STA
tumors is at least in part related to increased Kit and/or Mitf
levels, especially given the growth inhibitory effect of imatinib
treatment, however, other possible mediators of this effect are
not excluded. Additionally, increased Mitf may also play a role
in the elevated proliferation rates observed in Pten/Braf/Bcat-
STA melanomas, as Mitf has been shown to be an important
integrator of upstream signaling pathways in regulating754, December 13, 2011 ª2011 Elsevier Inc. 751
Cancer Cell
b-Catenin Controls Melanoma Metastasisproliferation and differentiation in the melanocytic lineage.
Increased Akt activity, however, is likely due to transcriptional
upregulation of Pin1, which enhances Akt stability, leading to
an increase in Akt protein levels, and ultimately activated Akt.
This link between Wnt signaling and Akt in melanoma is likely
also important in human melanomas, where increased PIN1
transcription is associated with increased Wnt/MITF. As PIN1
has also been shown to potentiate the effects of additional onco-
genes, such as Jun (Han et al., 2011), mutant p53 (Girardini et al.,
2011), and Cyclin D1 (Li et al., 2006), PIN1-dependent effects are
likely to play a broad role in cancer.
Components of the MAPK and also the PI3K/Akt pathways
are central targets for new cancer therapeutics. For example,
vemurafenib (PLX4032), a mutant Braf inhibitor has been
shown to improve survival in late-stage melanoma patients
with Braf mutations (Chapman et al., 2011). Along these lines,
understanding how simultaneous activation of additional
signaling pathways in a given tumor can impact inhibitor-tar-
geted pathways is essential and may assist in understanding
why some patients with a given driver mutation respond differen-
tially to treatment with the same inhibitor. In this context, it is
particularly noteworthy that changes to b-catenin can have
such profound effects to both the MAPK and PI3K/Akt signaling
pathways.
Here we have described several mouse models of melanoma
that have provided fundamental insight into mechanisms by
which b-catenin/Wnt signaling alterations can impact mela-
noma formation and progression in vivo. Extensive analyses
were conducted in order to ensure that these models closely
resemble human melanomas with analogous genetic changes
and cellular phenotypes. Faithful recapitulation of human mela-
noma, combined with features, such as rapid tumor growth and
reproducible metastasis to lymph nodes and lung, make this
model attractive for future studies in melanoma.
EXPERIMENTAL PROCEDURES
Mouse Strains and In Vivo Experiments
The Ctnnb1lox, E-cadherinlox, and TRE::Met strains were obtained from Jack-
son Labs. These mice were genotyped and assayed for recombination using
PCR as described previously (Brault et al., 2001; Wang et al., 2001; Boussadia
et al., 2002). The Tyr-CreER, Ptenlox, BrafCA, and Ctnnb1loxex3 alleles have also
been described previously and were genotyped and assayed for recombina-
tion using PCR (Harada et al., 1999; Dankort et al., 2009). The Tyr::rtTA strain
was obtained from MMHCC and genotyped as described previously (Chin
et al., 1999). All strains were maintained on a mixed C57BL/6, FVB, 129 back-
ground. For imatinib experiments, Pten/Braf/Bcat-STAmice were treated daily
with 200mg/kg imatinib (LC Laboratories) in water by oral gavage. All experi-
ments involving animals were reviewed and approved by the Yale Institutional
Animal Care and Use Committee.
Immunohistochemistry, Immunofluoresence, and Western Blotting
Immunofluoresence and immunohistochemistry were performed on formalin-
fixed, paraffin-embedded, and frozen tumor sections. Western blotting was
performed using standard methods on uncultured, macrodissected tumor
protein lysates or lysates from cultured human melanoma cell lines.
RNA Purification and qRT-PCR
Total RNA was isolated from homogenous portions of macrodissected, uncul-
tured tumors. cDNA was prepared for qRT-PCR analysis using SYBR green
detection methods andDDCt quantification relative to an endogenous GAPDH
control.752 Cancer Cell 20, 741–754, December 13, 2011 ª2011 Elsevier IncStatistical Analyses
Kaplan-Meyer survival curves were compiled using Prism statistical analysis
software. Significance was assessed using the Log-rank (Mantel-Cox) test.
For comparison of pooled data between two different groups, unpaired t tests
were used to determine significance. For comparison of data among three
groups, one-way ANOVA was used to determine significance. R was used
for hierarchical clustering, and Fisher’s Exact test was used to determine
significance for contingency table analysis.ACCESSION NUMBERS
Microarray datasets were deposited in the National Center for Biotechnology
Information’s Gene Expression Omnibus database with the accession number
GSE32907.SUPPLEMENTAL INFORMATION
Supplemental information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at
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